Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2023), Diabetes Obes Metab
Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study.
Journal article
Xu S. et al, (2022), Cardiovasc Diabetol, 21
Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials.
Journal article
Preiss D. et al, (2022), Diabetes Care, 45, e1 - e2
The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized trials
Conference paper
Preiss D. et al, (2022), DIABETES RESEARCH AND CLINICAL PRACTICE, 186
Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance.
Journal article
Xu S. et al, (2021), J Diabetes, 13, 817 - 826
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Journal article
Hundertmark MJ. et al, (2021), ESC Heart Fail, 8, 2580 - 2590
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.
Journal article
Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88.
Journal article
Lind M. et al, (2021), Diabetes Care
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis.
Journal article
Juraschek SP. et al, (2021), Ann Intern Med, 174, 58 - 68
Refeeding risks in patients requiring intravenous nutrition support: Results of a two-centre, prospective, double-blind, randomised controlled trial
Journal article
Ambrose T. et al, (2021), Clinical Nutrition ESPEN
Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Journal article
Wamil M. et al, (2020), Diabetes Res Clin Pract, 170
Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.
Journal article
Zhou JJ. et al, (2020), Diabetologia, 63, 2482 - 2485
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
Journal article
Donnelly LA. et al, (2020), Diabetes Care, 43, 2493 - 2499
Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis.
Conference paper
Juraschek SP. et al, (2020), HYPERTENSION, 76
Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
Journal article
Gerstein HC. et al, (2020), Diabetes Care, 43, 2242 - 2247
Risk of anaemia with metformin use: A MASTERMIND study
Conference paper
Donnelly LA. et al, (2020), DIABETIC MEDICINE, 37, 179 - 179
Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
Journal article
Agbaje OF. et al, (2020), Diabetes Res Clin Pract, 166
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Journal article
Coleman RL. et al, (2020), Diabetes Obes Metab, 22, 1151 - 1156